23 results on '"Ji, Shunrong"'
Search Results
2. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study.
- Author
-
Li, Zheng, Zhuo, Qifeng, Li, Borui, Liu, Mengqi, Chen, Chen, Shi, Yihua, Xu, Wenyan, Liu, Wensheng, Ji, Shunrong, Yu, Xianjun, and Xu, Xiaowu
- Subjects
NEOADJUVANT chemotherapy ,PANCREATICODUODENECTOMY ,PANCREATIC cancer ,LYMPHADENECTOMY ,PANCREATIC duct ,LAPAROSCOPIC surgery - Abstract
Background: There is no evidence supporting the feasibility of laparoscopic pancreaticoduodenectomy (LPD) compared to open pancreatoduodenectomy (OPD) following neoadjuvant chemotherapy (NACT) for pancreatic ductal adenocarcinoma (PDAC). Methods: The clinical data of consecutive patients with borderline resectable PDAC who received NACT and underwent either LPD or OPD between January 2020 and December 2022 at Fudan University Shanghai Cancer Center was prospectively collected and retrospectively analyzed. Results: The analysis included 57 patients in the OPD group and 20 in the LPD group. Following NACT, the LPD group exhibited a higher median CA19-9 decrease rate compared to the OPD group (85.3% vs. 66.9%, P = 0.042). Furthermore, 3 anatomically borderline PDACs in the LPD group and 5 in the OPD group were downstaged into resectable status (30.0% vs. 12.3%, P = 0.069). According to RECIST criteria, 51 (66.2%) patients in the entire cohort were evaluated as having stable disease. The median operation time for the LPD group was longer than the OPD group (419 vs. 325 min, P < 0.001), while the venous resection rate was 35.0% vs. 43.9%, respectively (P = 0.489). There was no difference in the number of retrieved lymph nodes, with a median number of 18.5 in the LPD group and 22 in the OPD group, and the R1 margin rate (15.0% vs. 12.3%) was also comparable. The incidence of Clavien-Dindo complications (35.0% vs. 66.7%, P = 0.018) was lower in the LPD group compared to the OPD group. Multivariable regression analysis revealed that a tumor diameter > 3 cm before NACT (HR 2.185) and poor tumor differentiation (HR 1.805) were independent risk factors for recurrence-free survival, and a decrease rate of CA19-9 > 70% (OR 0.309) was a protective factor for early tumor recurrence and overall survival. Conclusions: LPD for PDAC following NACT is feasible and oncologically equivalent to OPD. Effective control of CA19-9 levels is beneficial in reducing early tumor recurrence and improving overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer
- Author
-
Liu, Mengqi, Liu, Wensheng, Qin, Yi, Xu, Xiaowu, Yu, Xianjun, Zhuo, Qifeng, and Ji, Shunrong
- Published
- 2020
- Full Text
- View/download PDF
4. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
- Author
-
Liang, Chen, Shi, Si, Meng, Qingcai, Liang, Dingkong, Ji, Shunrong, Zhang, Bo, Qin, Yi, Xu, Jin, Ni, Quanxing, and Yu, Xianjun
- Published
- 2018
- Full Text
- View/download PDF
5. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
- Author
-
Qin, Yi, Hu, Qiangsheng, Xu, Jin, Ji, Shunrong, Dai, Weixing, Liu, Wensheng, Xu, Wenyan, Sun, Qiqing, Zhang, Zheng, Ni, Quanxing, Zhang, Bo, Yu, Xianjun, and Xu, Xiaowu
- Published
- 2019
- Full Text
- View/download PDF
6. SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD.
- Author
-
Lu, Zekun, Hu, Qiangsheng, Qin, Yi, Yang, Hao, Xiao, Bingkai, Chen, Weibo, Ji, Shunrong, Zu, Guangchen, Wang, Zhiliang, Fan, Guixiong, Xu, Xiaowu, and Chen, Xuemin
- Subjects
PANCREATIC cancer ,INHIBITION of cellular proliferation ,CELL analysis ,CELL proliferation ,CANCER cells - Abstract
Background: As an oncogene, SETD8 can promote tumour growth and tumour cell proliferation. This study aims to reveal the relationship between SETD8 and ferroptosis in pancreatic cancer and its role in pancreatic cancer to provide a possible new direction for the comprehensive treatment of pancreatic cancer. Methods: The downstream targets were screened by RNA sequencing analysis. Western blot, Real-time Quantitative PCR (qPCR) and immunohistochemistry showed the relationship between genes. Cell proliferation analysis and cell metabolite analysis revealed the function of genes. Chromatin immunoprecipitation (CHIP) assays were used to study the molecular mechanism. Results: The potential downstream target of SETD8, RRAD, was screened by RNA sequencing analysis. A negative correlation between SETD8 and RRAD was found by protein imprinting, Real-time Quantitative PCR (qPCR) and immunohistochemistry. Through cell proliferation analysis and cell metabolite analysis, it was found that RRAD can not only inhibit the proliferation of cancer cells but also improve the level of lipid peroxidation of cancer cells. At the same time, chromatin immunoprecipitation analysis (CHIP) was used to explore the molecular mechanism by which SETD8 regulates RRAD expression. SETD8 inhibited RRAD expression. Conclusions: SETD8 interacts with the promoter region of RRAD, which epigenetically silences the expression of RRAD to reduce the level of lipid peroxidation in pancreatic cancer cells, thereby inhibiting ferroptosis in pancreatic cancer cells and resulting in poor prognosis of pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.
- Author
-
Zhang, Zheng, Wang, Fei, Li, Zheng, Ye, Zeng, Zhuo, Qifeng, Xu, Wenyan, Liu, Wensheng, Liu, Mengqi, Fan, Guixiong, Qin, Yi, Zhang, Yue, Chen, Xuemin, Yu, Xianjun, Xu, Xiaowu, and Ji, Shunrong
- Subjects
LYMPHADENECTOMY ,NEUROENDOCRINE tumors ,PANCREATIC tumors ,LYMPHATIC metastasis ,TUMOR grading ,PROGNOSIS ,PANCREATIC cancer - Abstract
Background: Although some factors that predict the prognosis in pancreatic neuroendocrine tumor (pNET) have been confirmed, the predictive value of lymph node metastasis (LNM) in the prognosis of pNETs remains conflicting and it is not clear whether regional lymphadenectomy should be performed in all grades of tumors.Methods: We included pNET patients undergoing surgery in Shanghai pancreatic cancer institute (SHPCI). The risk factors for survival were investigated by the Kaplan-Meier method and Cox regression model. We evaluated the predictors of LNM using Logistic regression.Results: For 206 patients in the SHPCI series, LNM was an independent prognostic factor for entire cohort suggested by multivariate Cox regression analysis. LNM (P = 0.002) predicted poorer overall survival (OS) in grade 2/3 cohort, but there is no significant association between LNM and OS in grade 1 cohort. Grade (P < 0.001) and size (P = 0.049) predicted LNM in entire cohort. Grade (P = 0.002) predicted LNM while regardless of size in grade 2/3 cohort.Conclusions: Based on our own retrospective data obtained from a single center series, LNM seems to be associated with poorer outcome for patients with grade 2/3 and/or grade 1 > 4 cm tumors. On the other way, LNM was seems to be not associated with prognosis in patients with grade 1 tumors less than 4 cm. Moreover, tumor grade and tumor size seem to act as independent predictors of LNM. Thus, regional lymphadenectomy should be performed in grade 2/3 patients but was not mandatory in grade 1 tumors < 4 cm. It is reasonable to perform functional sparing surgery for grade 1 patients or propose a clinical-radiological monitoring. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway.
- Author
-
Xu, Junfeng, Li, Zheng, Zhuo, Qifeng, Ye, Zeng, Fan, Guixiong, Gao, Heli, Ji, Shunrong, Yu, Xianjun, Xu, Xiaowu, Liu, Wensheng, and Xu, Wenyan
- Subjects
CANCER cell growth ,PANCREATIC cancer ,TUMOR growth ,GENE expression profiling ,CELL cycle ,PROTEOLYSIS - Abstract
Background: The neddylation pathway is aberrantly overactivated in multiple human cancers and has been indicated as an effective target for anticancer therapy in clinical trials. We aimed to study whether the neddylation pathway is upregulated in pancreatic cancer and whether pevonedistat, a first-in-class anticancer agent specifically targeting this pathway, will suppress cancer tumorigenesis and progression. Methods: We evaluated the expression pattern of neddylation pathway components in 179 pancreatic adenocarcinoma (PAAD) compared with 171 normal tissues from The Cancer Genome Atlas (TCGA) dataset and further assessed PAAD patient prognosis with high neddylation pathway expression via Gene Expression Profiling Interactive Analysis (GEPIA). We then analyzed malignant cancer phenotypes both in vitro and in vivo , as well as intrinsic molecular mechanisms upon pevonedistat treatment. Results: We found that the neddylation pathway was hyperactivated in pancreatic cancer. Patients with high neddylation pathway expression exhibited worse prognoses. Pevonedistat significantly inhibited the cancer cell cycle, cell growth, and proliferation; increased cell apoptosis; and decreased cancer cell xenografts in a mouse model. Mechanistically, pevonedistat treatment and the siRNA knockdown neddylation pathway were able to remarkably induce the accumulation of Wee1, p27, and p21. Further mechanistic studies revealed that pevonedistat mainly impaired the ubiquitination level and delayed the protein degradation of Wee1, p27, and p21. Conclusions: Our results showed that pevonedistat targeted the overexpression of the neddylation pathway in pancreatic cancer to induce cell growth suppression by inducing the accumulation of the cell cycle regulators Wee1, p27, and p21, which provides sound evidence for the clinical trial of pevonedistat for pancreatic cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab‐paclitaxel in pancreatic cancer.
- Author
-
Zhang, Zheng, Ji, Shunrong, Hu, Qiangsheng, Zhuo, Qifeng, Liu, Wei, Xu, Wenyan, Liu, Wensheng, Liu, Mengqi, Ye, Zeng, Fan, Guixiong, Xu, Xiaowu, Yu, Xianjun, and Qin, Yi
- Subjects
- *
PACLITAXEL , *GEMCITABINE , *PANCREATIC cancer , *CELL death , *MAGNETIC resonance imaging , *MEDICAL research - Abstract
The baseline is referring to the patient before therapy administration gl Interesting, VEGF promotes gemcitabine resistance in pancreatic cancer cells (Figures 2A and 2B). Finally, we silenced c-Myc in VEGF-stimulated MIA PaCa-2 and SW1990 cells, and found that c-Myc suppression or knockdown could reverse the effects of VEGF on the IC50 values of gemcitabine of pancreatic cancer cells (Figures S2E and S2F). The baseline is referring to the patient before therapy administration. gl GLO:F2H7/01aug21:ctm2398-sup-0002-FigureS2.jpg PHOTO (COLOR): Figure S2 Silencing c-Myc reverses the effect of VEGF on RRM1. Dear Editor, The regimen of nab-paclitaxel and gemcitabine (AG) has been widely used as the first-line chemotherapy for advanced pancreatic cancer; the prolonged survival time is still less than 2 months.1 Kim et al demonstrated that paclitaxel can induce vascular endothelial growth factor-A (VEGF) expression which could facilitate the survival of neoplastic and tumor cells, thus protecting both endothelial and stroma cells from cytotoxic death while promoting angiogenesis.2-4 To explore the neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC) treated with AG or gemcitabine alone, we first examined the I K SP trans sp i value in the tumor by Dynamic contrast enhancement magnetic resonance imaging (DCE-MRI). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
10. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF‐κB‐IL‐18 feedback loop.
- Author
-
Sun, Qiqing, Fan, Guixiong, Zhuo, Qifeng, Dai, Weixing, Ye, Zeng, Ji, Shunrong, Xu, Wenyan, Liu, Wensheng, Hu, Qiangsheng, Zhang, Zheng, Liu, Mengqi, Yu, Xianjun, Xu, Xiaowu, and Qin, Yi
- Subjects
PANCREATIC cancer ,METASTASIS ,CANCER cell motility ,CANCER invasiveness ,CANCER cell proliferation - Abstract
Objectives: Accumulated evidence suggests that Pin1 contributes to oncogenesis of diverse cancers. However, the underlying mechanism of oncogenic function of Pin1 in PDAC requires further exploration. Materials and Methods: IHC was performed using PDAC tissues. Western blot, PCR, immunofluorescence and transwell were performed using cell lines. GSEA were applied for possible downstream pathways. ChIP assay and dual luciferase were used for assessment of transcriptional activity. Results: Both Pin1 and IL‐18 levels are increased in primary PDAC tissues and that their levels are positively correlated. High expression of IL‐18 is a predictor of poor prognoses. Pin1 promoted pancreatic cancer cell proliferation and motility by increasing IL‐18 expression, while Pin1 knockdown also inhibited the tumour‐promoting effect of IL‐18. Both Pin1 and IL‐18 could enhance the NFκB activity in pancreatic cancer cells. When bound to the p65 protein, Pin1 promoted p65 phosphorylation and its nuclear translocation. In the nucleus, Pin1 and p65 simultaneously bound to the IL‐18 promoter and enhanced IL‐18 transcription. In addition, recruitment of p65 to the IL‐18 promoter was decreased in Pin1‐silenced cells. Conclusions: Our study improves the understanding of Pin1 in tumour‐promoting inflammation in PDAC, which is a hallmark of cancer; Pin1 interacted with p65 in PDAC and enhanced NF‐κB signalling and downstream transcriptional activation of IL‐18, with increased IL‐18 continuously activating NF‐κB signalling, which then forms a positive feedback loop. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Homeodomain‐interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.
- Author
-
Qin, Yi, Hu, Qiangsheng, Ji, Shunrong, Xu, Jin, Dai, Weixing, Liu, Wensheng, Xu, Wenyan, Sun, Qiqing, Zhang, Zheng, Ni, Quanxing, Yu, Xianjun, Zhang, Bo, and Xu, Xiaowu
- Subjects
PANCREATIC cancer ,PROTEIN kinases ,GLYCOLYSIS ,GLUCOSE analysis ,PROTEIN stability ,EXTRACELLULAR signal-regulated kinases - Abstract
Objectives: To investigate the roles of the homeodomain‐interacting protein kinase (HIPK) family of proteins in pancreatic cancer prognosis and the possible molecular mechanism. Materials and Methods: The expression of HIPK family genes and their roles in pancreatic cancer prognosis were analysed by using The Cancer Genome Atlas (TCGA). The roles of HIPK2 in pancreatic cancer proliferation and glycolysis were tested by overexpression of HIPK2 in pancreatic cancer cells, followed by cell proliferation assay, glucose uptake analysis and Seahorse extracellular flux analysis. The mechanism of action of HIPK2 in pancreatic cancer proliferation and glycolysis was explored by examining its effect on the ERK/cMyc axis. Results: Decreased HIPK2 expression indicated worse prognosis of pancreatic cancer. Overexpression of HIPK2 in pancreatic cancer cells decreased cell proliferation and attenuated aerobic glycolysis, which sustained proliferation of cancer cells. HIPK2 decreased cMyc protein levels and expression of cMyc‐targeted glycolytic genes. cMyc was a mediator that regulated HIPK2‐induced decrease in aerobic glycolysis. HIPK2 regulated cMyc protein stability via ERK activation, which phosphorylated and controlled cMyc protein stability. Conclusions: HIPK2 suppressed proliferation of pancreatic cancer in part through inhibiting the ERK/cMyc axis and related aerobic glycolysis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
- Author
-
Hu, Qiangsheng, Qin, Yi, Xiang, Jinfeng, Liu, Wensheng, Xu, Wenyan, Sun, Qiqing, Ji, Shunrong, Liu, Jiang, Zhang, Zheng, Ni, Quanxing, Xu, Jin, Yu, Xianjun, and Zhang, Bo
- Subjects
PANCREATIC cancer genetics ,DEOXYCYTIDINE ,DRUG metabolism ,TRANSCRIPTION factors ,HOMEOSTASIS - Abstract
Abstract: Objectives: Decreased deoxycytidine kinase (dCK) expression is a reported indicator of gemcitabine efficacy in pancreatic cancer, due to the impact of this kinase on gemcitabine metabolism. The transcription factor NF‐E2 p45‐related factor 2 (NRF2, also called Nfe2l2), a master regulator of redox homoeostasis, has been reported to tightly control the expression of numerous ROS‐detoxification genes and participates in drug resistance. However, the contribution of dCK to the NRF2 signalling axis has seldom been discussed and needs investigation. Materials and methods: By overexpressing dCK in pancreatic cancer cells, we assessed the impact of dCK on NRF2 transcriptional activity. Furthermore, we measured the impact of dCK expression on the intracellular redox balance and reactive oxygen species (ROS) production. By utilizing immunohistochemical staining and tissues from pancreatic cancer patients, we assessed the correlation between dCK and NRF2 expression. Through proliferation and metastasis assays, we examined the impact of dCK expression on cell proliferation and metastasis. Results: dCK negatively regulates NRF2 transcriptional activity, leading to the decreased expression of ARE‐driven antioxidant genes. In addition, dCK negatively regulates intracellular redox homoeostasis and ROS production. Negative correlations between dCK and NRF2 levels in pancreatic cancer cell lines and patient samples were observed. In vitro cell line studies suggested that dCK negatively regulated proliferation and metastasis. Conclusion: Decreased dCK expression promotes NRF2‐driven antioxidant transcription, which further enhances gemcitabine treatment resistance, forming a feedback loop. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration.
- Author
-
Schoppmeyer, Rouven, Zhao, Renping, Cheng, He, Hamed, Mohamed, Liu, Chen, Zhou, Xiao, Schwarz, Eva C., Zhou, Yan, Knörck, Arne, Schwär, Gertrud, Ji, Shunrong, Liu, Liang, Long, Jiang, Helms, Volkhard, Hoth, Markus, Yu, Xianjun, and Qu, Bin
- Abstract
The actin-binding protein profilin1 (PFN1) plays a central role in actin dynamics, which is essential for cytotoxic T lymphocyte (CTL) functions. The functional role of PFN1 in CTLs, however still remains elusive. Here, we identify PFN1 as the only member of the profilin family expressed in primary human CD8
+ T cells. Using in vitro assays, we find that PFN1 is a negative regulator of CTL-mediated elimination of target cells. Furthermore, PFN1 is involved in activation-induced lytic granule (LG) release, CTL migration and modulation of actin structures at the immunological synapse (IS). During CTL migration, PFN1 modulates the velocity, protrusion formation patterns and protrusion sustainability. In contrast, PFN1 does not significantly affect migration persistence and the rates of protrusion emergence and retraction. Under in vitro conditions mimicking a tumor microenvironment, we show that PFN1 downregulation promotes CTL invasion into a 3D matrix, without affecting the viability of CTLs in a hydrogen peroxide-enriched microenvironment. Highlighting its potential relevance in cancer, we find that in pancreatic cancer patients, PFN1 expression is substantially decreased in peripheral CD8+ T cells. Taken together, we conclude that PFN1 is a negative regulator for CTL-mediated cytotoxicity and may have an impact on CTL functionality in a tumor-related context. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer.
- Author
-
Ji, Shunrong, Zhang, Bo, Liu, Jiang, Qin, Yi, Liang, Chen, Shi, Si, Jin, Kaizhou, Liang, Dingkong, Xu, Wenyan, Xu, Huaxiang, Wang, Wenquan, Wu, Chuntao, Liu, Liang, Liu, Chen, Xu, Jin, Ni, Quanxing, and Yu, Xianjun
- Subjects
- *
ALDOLASES , *ONCOGENES , *PANCREATIC cancer treatment , *CANCER invasiveness , *CANCER cells , *CANCER genetics , *GENE expression , *ENZYME metabolism , *REACTIVE oxygen species , *ANIMALS , *CELL lines , *CELLULAR signal transduction , *ENZYMES , *GLYCOLYSIS , *GLYCOPROTEINS , *METASTASIS , *MICE , *PANCREATIC tumors , *XENOGRAFTS , *HIGH throughput screening (Drug development) , *DUCTAL carcinoma - Abstract
Pancreatic cancer is an aggressive and devastating disease that is characterized by uncontrolled progression, invasiveness and resistance to conventional treatment. In the past decades, much effort has been given to cancer genetics and pathological classification of this disease. Our previous study has uncovered a subgroup of patients with poor outcome, which is characterized by serum signature of CEA(+)/CA125(+)/CA19-9 ≥ 1000 U/mL; however, the underlying biology mechanism remains poorly understood. By using high-throughput screening analysis, we analyzed gene expression signature in highly malignant patients with serum markers of CEA(+)/CA125(+)/CA19-9 ≥ 1000 U/mL. Multiple differentially expressed genes were identified, many of which were closely related with cancer metabolic changes. Treatment of pancreatic cancer cell lines PANC-1 with transforming growth factor-β (TGF-β), which was commonly used to induce metastasis, has uncovered that the glycolytic process and antioxidant response was up-regulated upon TGF-β stimulation. These results were consistent with the high-throughput screening analysis. Subsequent analysis indicated that among glycolytic genes, aldolase A (ALDOA) increased the most significantly upon TGF-β treatment. Further in vitro and in vivo results demonstrated that ALDOA was associated with proliferation and metastasis of pancreatic cancer cells. Moreover, ALDOA predicted poor prognosis of pancreatic cancer, partially due to its role in E-cadherin expression regulation, and the results were further validated by analysis of the correlation between ALDOA and E-cadherin expression in pancreatic cancer tissue samples. Mechanistically, the role of ALDOA in pancreatic cancer might attribute to its regulation of c-Myc, HIF1α and NRF2 (Nuclear Factor, Erythroid 2-Like 2), which were key regulators of glycolysis and antioxidant response control. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer.
- Author
-
Shi, Si, Ji, Shunrong, Qin, Yi, Xu, Jin, Zhang, Bo, Xu, Wenyan, Liu, Jiang, Long, Jiang, Liu, Chen, Liu, Liang, Ni, Quanxing, and Yu, Xianjun
- Subjects
- *
TUMOR markers , *PANCREATIC cancer , *RADIOPHARMACEUTICALS , *POSITRON emission tomography , *ONCOGENES , *BLOOD serum analysis - Abstract
Pancreatic cancer is an aggressive and lethal disease with an overall 5-year survival rate of only 5%. Studies have demonstrated the ability of 18 F-fludrodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) to measure the metabolic tumor burden in patients with various tumors, including pancreatic cancer. In a previous study, we investigated the predictive significance of the metabolic tumor burden in terms of the metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this study, we analyzed the correlation between metabolic tumor burden and the status of the KRAS, TP53, CDKN2A/p16, and SMAD4/DPC4 genes. Our results showed that the metabolic tumor burden was associated with oncogenomic alterations that reflected the abnormal expression of carbohydrate metabolic enzymes (GLUT1, ALDOA and FBP1). We also identified a linear correlation between serum tumor markers and the metabolic tumor burden. To estimate the metabolic tumor burden when 18 F-FDG PET/CT is not available, we used the linear regression models to establish equations for MTV and TLG using CA19-9 and CA125 as independent variables. Our results suggest that the metabolic tumor burden, as evaluated by 18 F-FDG PET/CT or estimated by serum tumor markers, may be suitable for monitoring treatment response and disease progression of pancreatic cancer. Further research is needed to better understand why pancreatic cancer patients with abnormal expressions of TP53, CDKN2A/p16, and SMAD4/DPC4 get high metabolic tumor burden. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Transcription factor EB reprograms branched‐chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1.
- Author
-
Wang, Ting, Hu, Qiangsheng, Li, Borui, Fan, Guixiong, Jing, Desheng, Xu, Junfeng, Hu, Yuheng, Dang, Qin, Ji, Shunrong, Zhou, Chenjie, Zhuo, Qifeng, Xu, Xiaowu, Qin, Yi, Yu, Xianjun, and Li, Zheng
- Subjects
- *
TRANSCRIPTION factors , *PANCREATIC cancer , *GENETIC transcription regulation , *AMINO acid metabolism , *CANCER invasiveness , *METABOLIC reprogramming - Abstract
Pancreatic cancer cells have a much higher metabolic demand than that of normal cells. However, the abundant interstitium and lack of blood supply determine the lack of nutrients in the tumour microenvironment. Although pancreatic cancer has been reported to supply extra metabolic demand for proliferation through autophagy and other means, the specific regulatory mechanisms have not yet been elucidated. In this study, we focused on transcription factor EB (TFEB), a key factor in the regulation of autophagy, to explore its effect on the phenotype and role in the unique amino acid utilisation pattern of pancreatic cancer cells (PCCs). The results showed that TFEB, which is generally highly expressed in pancreatic cancer, promoted the proliferation and metastasis of PCCs. TFEB knockdown inhibited the proliferation and metastasis of PCCs by blocking the catabolism of branched‐chain amino acids (BCAAs). Concerning the mechanism, we found that TFEB regulates the catabolism of BCAAs by regulating BCAT1, a key enzyme in BCAA metabolism. BCAA deprivation alone did not effectively inhibit PCC proliferation. However, BCAA deprivation combined with eltrombopag, a drug targeting TFEB, can play a two‐pronged role in exogenous supply deprivation and endogenous utilisation blockade to inhibit the proliferation of pancreatic cancer to the greatest extent, providing a new therapeutic direction, such as targeted metabolic reprogramming of pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer.
- Author
-
Hu, Qiangsheng, Qin, Yi, Ji, Shunrong, Xu, Wenyan, Liu, Wensheng, Sun, Qiqing, Zhang, Zheng, Liu, Mengqi, Ni, Quanxing, Yu, Xianjun, and Xu, Xiaowu
- Subjects
- *
PANCREATIC cancer , *GLYCOLYSIS , *TUMOR suppressor genes , *CANCER cell proliferation , *RINGS (Jewelry) - Abstract
UHRF1 (ubiquitin like with plant homeodomain and ring finger domains 1) is an epigenetic modifier that is overexpressed in some cancers, including pancreatic cancer, and mediates silencing of tumor suppressor genes. However, the role of UHRF1 in regulating pancreatic cancer metabolism and metastasis is not clear. In the present study, we demonstrated that silencing UHRF1 significantly inhibited aerobic glycolysis in pancreatic cancer cells. Furthermore, we demonstrated that UHRF1 knockdown decreased hypoxia inducible factor (HIF)1α levels and HIF1α targeted glycolytic genes. The Cancer Genome Atlas dataset analysis supported this observation. The Sirtuin (SIRT) family members regulate aerobic glycolysis in many cancers. We analyzed the correlation between UHRF1 and SIRT3-5 expression and found a significant negative correlation between UHRF1 and SIRT4. Further transcriptional and functional analysis demonstrates that SIRT4 is a downstream target of UHRF1 and negatively regulated aerobic glycolysis, cell proliferation and tumor growth. Our study identified a novel UHRF1/SIRT4 axis in regulation of pancreatic cancer cell proliferation, metabolism, and metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
- Author
-
Liu, Mengqi, Qin, Yi, Hu, Qiangsheng, Liu, Wensheng, Ji, Shunrong, Xu, Wenyan, Fan, Guixiong, Ye, Zeng, Zhang, Zheng, Xu, Xiaowu, Yu, Xianjun, and Zhuo, Qifeng
- Subjects
- *
PANCREATIC cancer , *MASS analysis (Spectrometry) , *NUCLEOTIDE sequence , *PROMOTERS (Genetics) , *CELL proliferation , *PANCREATIC intraepithelial neoplasia , *PANCREATIC surgery , *PANCREATIC tumors , *BIOCHEMISTRY , *PROTEINS , *PANCREAS , *ANIMAL experimentation , *PHOSPHATASES , *CELL physiology , *DUCTAL carcinoma , *PHENOMENOLOGY , *CELLULAR signal transduction , *PANCREATECTOMY , *DNA methylation , *TRANSFERASES , *GENES , *KAPLAN-Meier estimator , *GENE expression profiling , *CELL lines , *GENETIC techniques , *MICE , *CARRIER proteins - Abstract
Constitutive ERK1/2 activation has been frequently observed in pancreatic adenocarcinoma (PDAC). How ERK1/2 activation status been potentiated and maintained by epigenetic mechanisms has seldom been discussed in PDAC. In this study, we first examined the expression status of p-ERK1/2 in PDAC tissues by immunohistochemical staining and then screened possible epigenetic factors that displayed different expression status between p-ERK1/2 high and low groups by RNA profiling, and found that SETD8 displayed an increased expressional pattern in p-ERK1/2high patient group. Then the impact of SETD8 on the proliferation of PDAC cells were investigated on the basis of gain or loss-of-function assays. RNA sequencing assays were performed to screen potential SETD8 downstream targets that contribute to ERK1/2 activation. Mass spectrometry and transcriptional analysis, including dual-luciferase assay and chromatin immunoprecipitation assay (ChIP), were used to explore the molecular mechanisms that governing SETD8-mediated ERK1/2 activation. In vitro cell line studies and in vivo xenograft mouse model studies indicated that SETD8 promoted cell proliferation and increased tumor formation capacity of PDAC cell lines. Mechanism explorations uncovered that SETD8 suppressed the expression of DUSP10, which was responsible for dephosphorylation of ERK1/2. Mass spectrometry and transcriptional analysis results demonstrated that STAT3 interacted with SETD8 and recruited SETD8 to the promoter region of DUSP10, leading to epigenetic silencing of DUSP10 and the resultant activation of ERK1/2. In conclusion, SETD8 interacts with STAT3 on DUSP10 promoter region and epigenetically silences DUSP10 expression. Decreased DUSP10 expression in PDAC potentiates activation of ERK1/2 phosphorylation, resulting in unfavorable prognosis of PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer.
- Author
-
Liang, Chen, Qin, Yi, Zhang, Bo, Ji, Shunrong, Shi, Si, Xu, Wenyan, Liu, Jiang, Xiang, Jinfeng, Liang, Dingkong, Hu, Qiangsheng, Ni, Quanxing, Yu, Xianjun, and Xu, Jin
- Subjects
- *
PANCREATIC cancer , *GUANOSINE triphosphatase , *ADP-ribosylation factors , *WARBURG Effect (Oncology) , *CELL proliferation , *ADENOCARCINOMA , *CELL lines , *CELL physiology , *CELLULAR signal transduction , *GENETIC techniques , *ONCOGENES , *PROGNOSIS , *PROTEINS , *DUCTAL carcinoma - Abstract
Though significant progress has been made in the availability of diagnostic techniques and treatment strategies, pancreatic cancer remains a disease of high mortality rates. Therefore, there is an urgent need for a better understanding of the molecular mechanisms that governs the oncogenesis and metastasis process of pancreatic cancer. In our study, by using the Cancer Genome Atlas (TCGA) dataset analysis, we demonstrated that the small guanosine triphosphatase (GTPase) ADP-ribosylation factor 6 (ARF6) serves as a biomarker for predicting prognosis of pancreatic cancer. In vitro studies demonstrated that silencing ARF6 expression reduced cell proliferation and attenuated the Warburg effect. Moreover, we observed that ARF6 was a downstream target of Kras/ERK signaling pathway, and the strong correlation of expression between Kras and ARF6 in the TCGA dataset further confirmed this observation. Taken together, our novel findings suggest ARF6, a target of mutant Kras, may promote pancreatic cancer development by enhancing the Warburg effect. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma.
- Author
-
Liang, Chen, Qin, Yi, Zhang, Bo, Ji, Shunrong, Shi, Si, Xu, Wenyan, Liu, Jiang, Xiang, Jinfeng, Liang, Dingkong, Hu, Qiangsheng, Ni, Quanxing, Xu, Jin, and Yu, Xianjun
- Subjects
- *
PANCREATIC duct , *GENETIC polymorphisms , *TUMOR suppressor genes , *STROMAL cells , *LIPID metabolism , *GLUTAMINE metabolism , *CANCER - Abstract
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignant neoplasms. The recognized hallmarks of PDA are regarded to be downstream events of metabolic reprogramming. Because PDA is a heterogeneous disease that is influenced by genetic polymorphisms and changes in the microenvironment, metabolic plasticity is a novel feature of PDA. As intrinsic factors for metabolic plasticity, K-ras activation and mutations in other tumor suppressor genes induce abnormal mitochondrial metabolism and enhance glycolysis, with alterations in glutamine and lipid metabolism. As extrinsic factors, the acidic and oxygen/nutrient-deprived microenvironment also induces cancer cells to reprogram their metabolic pathway and hijack stromal cells (mainly cancer-associated fibroblasts and immunocytes) to communicate, thereby adapting to metabolic stress. Therefore, a better understanding of the metabolic features of PDA will contribute to the development of novel diagnostic and therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. New insights into perineural invasion of pancreatic cancer: More than pain.
- Author
-
Liang, Dingkong, Shi, Si, Xu, Jin, Zhang, Bo, Qin, Yi, Ji, Shunrong, Xu, Wenyan, Liu, Jiang, Liu, Liang, Liu, Chen, Long, Jiang, Ni, Quanxing, and Yu, Xianjun
- Subjects
- *
PANCREATIC cancer treatment , *PANCREATIC cancer , *BIOLOGICAL invasions , *CANCER relapse , *METASTASIS , *CANCER cells , *PROGNOSIS - Abstract
Pancreatic cancer is one of the most malignant human tumors. Perineural invasion, whereby a cancer cell invades the perineural spaces surrounding nerves, is acknowledged as a gradual contributor to cancer aggressiveness. Furthermore, perineural invasion is considered one of the root causes of the recurrence and metastasis observed after pancreatic resection, and it is also an independent predictor of prognosis. Advanced research has demonstrated that the neural microenvironment is closely associated with perineural invasion in pancreatic cancer. Therapy targeting the molecular mechanism of perineural invasion may enable the durable clinical treatment of this formidable disease. This review provides an overview of the present status of perineural invasion, the relevant molecular mechanisms of perineural invasion, pain and hyperglycemia associated with perineural invasion in pancreatic cancer, and the targeted therapeutics based on these studies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process.
- Author
-
Qin, Yi, Zhu, Wenwei, Xu, Wenyan, Zhang, Bo, Shi, Si, Ji, Shunrong, Liu, Jiang, Long, Jiang, Liu, Chen, Liu, Liang, Xu, Jin, and Yu, Xianjun
- Subjects
- *
PANCREATIC cancer , *CANCER cell growth regulation , *GENETIC regulation , *HYPOXIA-inducible factor 1 , *GLYCOLYSIS , *PROTEIN stability , *CANCER cell proliferation - Abstract
Highlights: [•] LSD1 was frequently up-regulated in pancreatic cancer. [•] LSD1 was associated with proliferation and tumorigenicity of pancreatic cancer cells. [•] LSD1 regulated glycolysis in pancreatic cancer cells. [•] LSD1 regulated HIF1α protein stability. [•] LSD1 could be regulated by HIF1α. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
23. Organoid model: A new hope for pancreatic cancer treatment?
- Author
-
Chen, Haidi, Zhuo, Qifeng, Ye, Zeng, Xu, Xiaowu, and Ji, Shunrong
- Subjects
- *
PANCREATIC cancer , *PANCREATIC tumors , *CANCER treatment , *PANCREATIC intraepithelial neoplasia , *THERAPEUTICS , *PROGNOSIS - Abstract
Pancreatic cancer is a rapidly progressing disease with a poor prognosis. We still have many questions about the pathogenesis, early diagnosis and precise treatment of this disease. Organoids, a rapidly emerging technology, can simulate the characteristics of pancreatic tumors. Using the organoid model of pancreatic cancer, we can study and explore the characteristics of pancreatic cancer, thereby effectively guiding clinical practice and improving patient prognosis. This review introduces the development of organoids, comparisons of organoids with other preclinical models and the status of organoids in basic research and clinical applications for pancreatic cancer. Unlabelled Image [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.